Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2Bi Armed Fresh PBMCs in mCRPC and MBC
NCT07441889Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Jun 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa) and breast cancer, sponsored by University of Virginia. Primary endpoint: Dose Limiting Toxicities at 5 weeks. Started Jun 2026; status: recruiting.
02
Conditions
prostate cancer (PCa)breast cancer
Beyond the preview
Go deeper on NCT07441889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441889.